Escalon Medical Corp. (NASDAQ:ESMC) trades at a significant discount to its peer group as the lack of investor (and analyst) following results in the successful “shrink to grow” strategy being ignored. The company is now a pure play with no debt, cash that represents ~20% of the market cap, overlooked tax assets and a significantly lower cash burn rate. Escalon Medical Corp. (NASDAQ:ESMC) stock performance was -9.47% in last session and finished the day at $1.53. Traded volume was 39,543.00million shares in the last session and the average volume of the stock remained 14.98K shares. The beta of the stock remained -0.82. Escalon Medical Corp. (NASDAQ:ESMC) insider ownership is 2.09%.

CorMedix Inc. (NYSEMKT:CRMD), a specialty pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of infectious diseases in both acute and chronic care settings, today announced that it will report 2013 financial results on Monday, March 31, 2014. The Company’s Chief Executive Officer, Randy Milby, will be hosting a conference call on Tuesday, April 1, 2014 at 9:00 a.m. ET to discuss the Company’s 2013 results. CorMedix Inc. (NYSEMKT:CRMD) dropped -5.64 percent to $2.51 Monday on volume of 198,938.00million shares. The intra-day range of the stock was $2.49 to $2.65. CorMedix Inc. (NYSEMKT:CRMD) has a market capitalization of $54.95million.

Ocera Therapeutics Inc (NASDAQ:OCRX) is a company with one main value driver, OCR002. Financially, the company is now sitting on $47.2 M and will be spending $30M in the 2014 financial year. Ocera Therapeutics Inc (NASDAQ:OCRX)’s stock on Mar 31, 2014 reported a decrease of -8.82% to the closing price of $10.55. Its fifty two weeks range is $2.00 -$19.94. The total market capitalization recorded $163.03million. The overall volume in the last trading session was 221,385.00million shares. In its share capital, OCRX has 15.45million outstanding shares.

Marina Biotech, Inc. (OTCMKTS:MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today that it plans to broadly apply its RNAi, antisense and microRNA therapeutics platform to develop drugs for rare diseases. On Monday, shares of Marina Biotech, Inc. (OTCMKTS:MRNA) dropped -17.59% to close the day at $0.890. Company return on investment (ROI) is -65.80% and its monthly performance is recorded as -29.37%. Marina Biotech, Inc. (OTCMKTS:MRNA) quarterly revenue growth is 206.90%.